Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OBETICHOLIC ACID vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Obeticholic acid is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces bile acid synthesis by inhibiting CYP7A1, increases bile acid clearance, and exerts anti-inflammatory and antifibrotic effects.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA,Off-label: Non-alcoholic steatohepatitis (NASH) with fibrosis (not FDA-approved)
Management of mild to moderate pain,Reduction of fever
5 mg orally once daily, may increase to 10 mg once daily if tolerated after 3 months; maximum dose 10 mg daily.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is approximately 24 hours (range 14–36 h) in patients with primary biliary cholangitis, allowing once-daily dosing. Steady-state is achieved in about 2 weeks.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT2B7; undergoes enterohepatic recirculation; minimal CYP450 metabolism.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily biliary, with minimal renal excretion (<3%). The drug and its conjugates are eliminated in feces following biliary secretion. Enterohepatic recirculation occurs.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
≥99% bound to serum proteins, primarily albumin.
10-25% bound to albumin at therapeutic concentrations.
Approximately 0.2–0.4 L/kg, indicating limited extravascular distribution, consistent with a compound undergoing extensive enterohepatic circulation.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral bioavailability is low (~1–2%) due to extensive first-pass metabolism in the liver. Food may reduce absorption.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis; use with caution.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B or C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients (<18 years).
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment recommended; use standard adult dosing with monitoring for tolerability due to potential age-related decline in hepatic function.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Risk of hepatic decompensation and liver failure in patients with compensated or decompensated cirrhosis (Child-Pugh class B or C). Ocaliva is contraindicated in patients with decompensated cirrhosis or prior hepatic decompensation.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Hepatic decompensation and liver failure in cirrhotic patients (Child-Pugh class B or C); not recommended in such patients without appropriate dose adjustment.,Severe pruritus: Manage with antihistamines, bile acid resins, or dose reduction.,Elevation of LDL-cholesterol: Monitor lipid levels and manage according to guidelines.,Dose adjustment required for moderate to severe hepatic impairment (Child-Pugh class B and C).
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class B or C) or prior hepatic decompensation,Hypersensitivity to obeticholic acid or any excipients
Hypersensitivity to acetaminophen or any component of the formulation
No specific food interactions are reported, but alcohol should be avoided due to potential hepatotoxicity. Bile acid binding resins (e.g., cholestyramine) may reduce absorption; separate administration by at least 4-6 hours.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Animal studies show fetal harm at exposures similar to human therapeutic doses. No adequate human studies. Avoid use in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenicity. Second/third trimester: risk of fetal bile acid toxicity.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Excretion in human milk unknown. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. M/P ratio not determined.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No dose adjustment recommendations established. Pregnancy may alter bile acid metabolism; consider lower starting dose due to potential for increased systemic exposure from altered hepatic transport.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Obeticholic acid is a farnesoid X receptor agonist used for primary biliary cholangitis (PBC). It increases bile acid excretion and may cause dose-dependent pruritus; start at 5 mg daily and titrate to 10 mg if tolerated. Monitor hepatic function closely due to risk of liver decompensation. Contraindicated in patients with complete biliary obstruction.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take obeticholic acid exactly as prescribed, usually once daily with or without food.,Common side effects include itching (pruritus), which may be severe; inform your doctor if it becomes bothersome.,Report any symptoms of liver problems such as jaundice, dark urine, or abdominal pain immediately.,Avoid alcohol while taking this medication.,Do not take additional bile acid binding resins (e.g., cholestyramine) within 4-6 hours of obeticholic acid.,Inform your healthcare provider of all other medications you are taking, especially warfarin or other blood thinners.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before starting this medication.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OBETICHOLIC ACID vs INJECTAPAP, answered by our medical review team.
OBETICHOLIC ACID is a Farnesoid X receptor agonist that works by Obeticholic acid is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces bile acid synthesis by inhibiting CYP7A1, increases bile acid clearance, and exerts anti-inflammatory and antifibrotic effects.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OBETICHOLIC ACID and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OBETICHOLIC ACID is: 5 mg orally once daily, may increase to 10 mg once daily if tolerated after 3 months; maximum dose 10 mg daily.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OBETICHOLIC ACID and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OBETICHOLIC ACID is classified as Category C. Animal studies show fetal harm at exposures similar to human therapeutic doses. No adequate human studies. Avoid use in pregnancy unless benefit outweighs risk. First trimester: po. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.